-
Product Insights
New![]()
Net Present Value Model: Prokidney Corp’s REACT
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
New![]()
Innovation and Patenting activity of Prokidney Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Prokidney Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Net Present Value Model: Verona Pharma Plc’s Ensifentrine
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rilparencel in Type 1 Diabetes (Juvenile Diabetes)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rilparencel in Type 1 Diabetes (Juvenile Diabetes) Drug Details: Rilparencel (REACT) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rilparencel in Chronic Kidney Disease (Chronic Renal Failure)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rilparencel in Chronic Kidney Disease (Chronic Renal Failure) Drug Details: Rilparencel (REACT) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DF-3001 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DF-3001 in Refractory Multiple Myeloma Drug Details:DF-3001 is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CKD-516 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CKD-516 in Solid Tumor Drug Details: CKD-516 (NOV-120401) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Navicixizumab (OMP-305B83) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMA-203 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMA-203 in Solid Tumor Drug Details: IMA-203 is under development for the treatment of solid...
-
Thematic Analysis
![]()
Pharma Industry Mergers and Acquisitions Deals by Top Themes in 2022 – Thematic Intelligence
Pharma Industry Mergers and Acquisitions Deals Report Overview The pharma sector witnessed 784 M&A deals worth $126 billion in 2022. North America lead the M&A activity in 2022. The top themes driving M&A activity in the pharma sector in 2022 were rare disease and precision & personalized medicine. The pharma industry M&A deals thematic intelligence report provides an overview of the global M&A activities in the pharma sector in 2022. The report identifies the themes driving most notable to deals...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.